Reference

Endogenous steroid content during spironolactone continuous treatment

Endogenous steroid content during spironolactone continuous treatment. Abshagen, U.; Spoerl, S.; Schoeneshoefer, M.; L'age, M.; Rennekamp, H.; Oelkers, W. (Med. Klin. Poliklin., Freie Univ. Berlin, Berlin, Ger.). Verh. Dtsch. Ges. Inn. Med., 82(2), 1893-6 (German) 1976. CODEN: VDGIA2. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) In healthy male patients given a Na deficient diet for 14 days and then given spironolactone [52-01-7] (3 .times. 100 mg) or triamterene [396-01-0] (2 .times. 100 mg) daily after 1 week, the cumulative neg. Na balance was not significantly higher with spironolactone treatment than with triameterene treatment. The plasma renin [9015-94-5] activity was doubled at the end of the treatment time in the case of the spironolactone treated subjects over that of the triamterene treated subjects. Plasma deoxycorticosterone [64-85-7] increased to 305% and corticosterone [50-22-6] to 263% of the starting level under the influence of spironolactone, whereas triamterene had no effect on these parameters. Plasma aldosterone increased steadily under the influence of triamterene while spironolactone first decreased plasma aldosterone on the 1st day and then slowly increased it until by the end of the expt. the level was higher than in the triamterene treated subjects. The possible mechanisms for the effects of spironolactone are discussed.

Spironolactone and canrenoate-K: Relative potency at steady state

Spironolactone and canrenoate-K: Relative potency at steady state. Ramsay, Lawrence; Asbury, Michael; Shelton, John; Harrison, Ian (Div. Sci. Affairs, G. D Searle and Co., Ltd., Bucks., Engl.). Clin. Pharmacol. Ther., 21(5), 602-9 (English) 1977. CODEN: CLPTAT. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Relative dose ratios of the mineralocorticoid antagonists spironolactone (I) [52-01-7] (100 mg and 200 mg daily) and canrenoate-K [2181-04-6] (200 mg daily) at steady state were defined in 6 healthy subjects with fludrocortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during I treatments were consistent with the law of mass action. The potency of canrenoate-K was 0.68 that of I on a wt. basis. Approx. 72% of the renal antimineralocorticoid activity of I could be attributed to the metabolite canrenone [976-71-6]. The results at steady state are contrasted with those of a previous study comparing single doses of I and canrenoate-K.